KC Safi

Consultant urological & laparoscopic surgeon. FRCS(Urol), FEBU. Endourology/ MIS urologic oncology. Jordan Hospital & Medical center, Amman -Jordan

[KC Safi @safi_kc]

@AhmedINazer @sbinhamrii @MAlKhameesMD @Aldughiman_MD @SMCH_Riyadh Beautiful dissection

[KC Safi @safi_kc]

@RomanCarvajal In such high urethral angle small prostate, Do we rally need full enucleation?
Or just the middle part?

[KC Safi @safi_kc]

@mahmoudlaimon @maheruro2000 Not yet
Hopefully never

[KC Safi @safi_kc]

Smiley Boari flap for distal multiple strictures after multiple laser stone surgery and failed endoscopic stricture dilation, with good bladder capacity can bridge >10 cm defect easily.

[Fernando GomezSancha @fgomsan]

Nationwide German analysis of urachal cancer (2006-2022): 2593 cases; only 530 underwent surgery. Partial cystectomy in 413, radical cystectomy in 117. Despite its aggressive nature, the majority were treated with an organ-sparing approach.

https://t.co/HclOipJ4kg

[Stacy Loeb, MD @LoebStacy]

Hot off the press from #asco26 & @NEJM - the PROTEUS trial of perioperative apalutamide in high risk #prostatecancer ⬇️

[Mirrors of Medicine @mirrorsmed]

Missed our webinar on first-line mUCa treatment? The replay is now available on demand.

👥 @GIZZIMarcoMd | @RotteySylvie
👩‍⚕️ Moderator: @b_szabados

🎥 Access the replay for free: https://t.co/twLNcsUhON

#UroOnc #mUCa #BladderCancer
@Oncoalert

[KC Safi @safi_kc]

https://t.co/08zMCu1mg9

[💙alison birtle @AlisonBirtle]

Here is a Treatment algorithm for Bone health management in patients with prostate cancer on @OpenMedicineHQ. Interactive, evidence-linked, open for discussion. Feedback welcome. #LivingAlgorithms
https://t.co/J7fMUb5ahP

[KC Safi @safi_kc]

@TFL_URO_APIS @uro_star @urosusy @so_uro @EUplatinum @TurkJUrol @AliZaid10072555 @drabhaymahajan @NEUS_Residents @knowuro @SoURPUA @UpstateUroRes @GRUrology @EndourologyT @Urologoentux @usiurolithiasis @amir_wagdi @MidAtlanticAUA Ideal answer would be : Should be addressed on CT and evaluated before bringing patient to OR.

[UrologyMSK @UrologyMSK]

@urogoldjournal publication by Joel Sheinfeld @RichMatulewicz et al:
Can Novel Biomarkers Augment Traditional Surveillance Paradigms in Early-Stage Testicular Germ Cell Tumors? Pre-Clinical Relapse Detection Using Micro-RNA-371a-3p and 372-3p Assay
https://t.co/4LV6lEyiXZ

[Michael Hofman @DrMHofman]

First images from the GE Omni 128 cm Total Body PET/CT 🚀

The new scanner detected a <5 mm local recurrence of prostate cancer missed by standard PSMA PET/CT - despite 79% shorter acquisition ⏱️

Delayed imaging boosted lesion uptake and informed dose-painted salvage RT 🎯

@JournalofNucMed @PeterMacCC @declangmurphy @_ShankarSiva
https://t.co/Kiq9PHC12X

[DR CARVAJAL @RomanCarvajal]

Real case: very low-risk prostate cancer (PSA 3.4 ng, Gleason 3+3, 2-12, ISUP 1) appropriate for active surveillance. A family seeks a second opinion; a surgical oncologist orders a PSMA PET-CT? and refers to medical oncology. The scan, performed at a low-experience center, is read as metastatic (bone and nodal), leading to unnecessary chemotherapy + ADT + ARPI.
When the patient returned to me, the findings did not match the clinical picture, so I recommended a second nuclear medicine review. Conclusion: rib and cervical “lesions” were inflammatory/benign uptake, not metastases. Likely technical issue: residual sodium fluoride in an aged PSMA radiotracer causing nonspecific bone uptake. No CT structural correlate.
Key takeaway: Integrate clinical context, pathology, and technical quality.
#prostatecancer

[Abdulrahman Alkanderi @DRAAA86]

I have performed numerous re-treatments post-REZUM surgery and encountered various complications, but this is the first time I have come across such a finding.. !!

Have you ever face similar findings?
@hazemelmansy1
@fgomsan
@Mohamedendourol
@dr_mohannad_ksa
@mohamed92902484
@trwherrmann

[KC Safi @safi_kc]

@Mohamedendourol @Endo_Sec_Eua @Moser_DanielC @toshutosh @LamideyNoury @KARLSTORZUro @DRAAA86 @noddy_urologist @Urologeman @UroHeClinicUK @BernardoNor9 Totally agree with your points.

[Fernando GomezSancha @fgomsan]

HoLEP as a cure of a metabolic problem. Interesting paper! Refractory hypernatremia in a 52yo male — BPH was the cause.

Sodium peaked at 162 mmol/L despite standard care. Diagnosis: partial urinary tract obstruction impairing renal medullary concentrating ability.

After HoLEP + cystolithotripsy: sodium normalized to 139.7 mmol/L.

https://t.co/EQK8w2SHTN
https://t.co/PSqfEB4wRN

[NEJM @NEJM]

Original Article: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (phase 3 KEYNOTE-905 trial) https://t.co/liPEVlPfHV

Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy https://t.co/wIH8w21yJg

#Oncology

[Laura Bukavina @LauraBukavinaMD]

Get updated @EUplatinum published results in interactive format on our WhatsApp channel https://t.co/mcDNVdlX8e such as 👇👇 from updated pure 01 5 year data https://t.co/Co0yAFiLp4

[Adam B. Weiner, MD @Adam_Weiner535]

🚨Tansdermal Estradiol (tE2) vs ADT for locally advanced #prostatecancer🚨

@NEJM New phase 3 RCT (PATCH/STAMPEDE-1)

🔑tE2 patches are noninferior to LHRH agonists for metastasis-free survival (n=1,360)

✅ 87.1% vs 85.9% 3-yr MFS
🌡️ Way fewer hot flashes (44% vs 89%)
🦴 Lower fracture rates
⚠️ More gynecomastia

🔥Same cancer control. Better side effect profile. Patient-applied. Cheaper.

👀Time to rethink ADT? 👀

@PCFnews @PCF_Science @UrologyTimes @renalandurology @urotoday

🔗https://t.co/xVByp9TljJ

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

@tompowles1 @weoncologists @Uromigos @kalasri3 Thanks for the shoutout Tom.
We need to help our patients and deliver a unified message:
The OS advantage seen with EV+P
relies on consolidation with Radical
Cystectomy + PLND
(not observation, not TMT)
#EAU26